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Potent Inhibitory Activity of Chimeric Oligonucleotides
Targeting Two Different Sites of Human Telomerase
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LORA DIMITROVA,1 EUGEN UHLMANN,3 and MARTIN VON JANTA-LIPINSKI1
ABSTRACT
Suppression of telomerase activity in tumor cells has been considered as a new anticancer strategy.
Here, we present chimeric oligonucleotides (chimeric ODNs) as a new type of telomerase inhibitor
that contains differently modified oligomers to address two different sites of telomerase: the RNA
template and a suggested protein motif. We have shown previously that phosphorothioate-modified
oligonucleotides (PS ODNs) interact in a length-dependent rather than in a sequence-dependent
manner, presumably with the protein part of the primer-binding site of telomerase, causing strong
inhibition of telomerase. In the present study, we demonstrate that extensions of these PS ODNs at
their 3-ends with an antisense oligomer partial sequence covering 11 bases of the RNA template
cause significantly increased inhibitory activity, with IC50 values between 0.60 and 0.95 nM in a Telo-
meric Repeat Amplification Protocol (TRAP) assay based on U-87 cell lysates. The enhanced in-
hibitory activity is observed regardless of whether the antisense part is modified (phosphodiester,
PO; 2-O-methylribosyl, 2-OMe/PO; phosphoramidate, PAM). However, inside intact U-87 cells,
these modifications of the antisense part proved to be essential for efficient telomerase inhibition 20
hours after transfection. In particular, the chimeric ODNs containing PAM or 2-OMe/PO modifica-
tions, when complexed with lipofectin, were most efficient telomerase inhibitors (ID50  0.04 and
0.06 M, respectively). In conclusion, ODNs of this new type emerged as powerful inhibitors of hu-
man telomerase and are, therefore, promising candidates for further investigations of the anticancer
strategy of telomerase inhibition.
INTRODUCTION
IT HAS BEEN SHOWN THAT most human tumors overex-press telomerase (Shay and Wright, 1996). Therefore,
activation of telomerase is considered an essential com-
ponent for the unlimited proliferative activity of cancer
cells (Hahn et al., 1999; Zhang et al., 1999). This enzyme
compensates for the loss of telomeric DNA at the ends of
chromosomes, which occurs during each round of DNA
replication. Thus, cancer and other immortal cells appear
to be capable of escaping growth arrest and apoptosis
which are triggered when telomeric DNA ends reach a
critical length. Long-term inhibition of telomerase activ-
ity has, therefore, gained considerable interest as a
promising strategy to change the immortal state of cancer
cells to a mortal one (Autexier, 1999). In fact, it has been
shown that disruption of the catalytic function of telo-
merase by mutations abolishes the tumorigenicity of hu-
man tumor cells in vivo (Hahn et al., 1999).
Human telomerase is composed of two essential com-
ponents, the catalytic protein subunit with reverse tran-
scriptase activity (hTERT) (Lingner et al., 1997; Counter
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et al., 1997) and the endogeneous RNA subunit (Feng et
al., 1995). In principle, either of these two subunits might
be targeted to inhibit telomerase enzyme activity. An at-
tractive target is the telomerase RNA part, especially the
11-nucleotide (nt) region used as template for synthesis
of new telomeric DNA, as it can be targeted by a corre-
sponding complementary nucleic acid, such as an anti-
sense agent. Thus, the expression of antisense RNA in
immortal human cells has been shown to induce not only
telomere shortening but also cell death, beginning after
23–26 cell doublings (Feng et al., 1995).
These results have, thus, initiated a growing number of
studies using oligonucleotides (ODNs) as potential inhib-
itors of telomerase activity, including hammerhead ri-
bozymes (Kanazawa et al., 1996; Wan et al., 1998), un-
modified antisense ODNs (Glukhov et al., 1998; Saretzki
et al., 1999), 25-oligoadenylate-linked ODNs directing
RNase L to cleave telomerase RNA (Kondo et al., 1998,
2001), and 2-O-methyl (2-OMe)-modified and 2-O-
methoxyethyl-modified oligoribonucleotides and locked
nucleic acid (LNA) oligomers (Pitts and Corey, 1998;
Elayadi et al., 2001, 2002). Peptide nucleic acids (PNAs)
proved to be most effective (Norton et al., 1996), and
their efficiency may be increased further by conjugation
with cationic peptides (Harrison et al., 1999).
At the cellular level, PNAs duplexed with DNA and
2-OMe RNAs have been described as most effective in-
hibitors of telomerase activity. In these PNA/DNA par-
tial duplex molecules, the DNA portion allows for effi-
cient transfection by means of cationic lipids (Hamilton
et al., 1999; Elayadi et al., 2001). Furthermore, long-term
treatment with 2-OMe-RNA derivatives or N3 
P5phosphoramidate (PAM) analogs was found to cause
telomere shortening, followed by cellular senescence and
apoptosis in tumor cells (Herbert et al., 1999, 2002).
Controversal results, however, have been reported for G-
rich phosphorothioate-modified ODNs (PS ODNs). They
were found to be less potent and selective than PNAs
(Norton et al., 1996), and their efficacy was thought to be
dependent on their ability to form G-quartets (Sharma et
al., 1997). In addition, they have been reported to exert a
direct growth-inhibiting effect on cell proliferation (Mata
et al., 1997; Ohnuma et al., 1997).
We have described that PS ODNs, although designed to
bind via Watson-Crick base pairing to the RNA template,
bind in a sequence-independent manner to telomerase pro-
tein, which could explain some of the conflicting results
(Matthes and Lehmann, 1999). The telomerase protein
hTERT is thought to have a specific site to fix the 5-end
of the primer, called primer binding site, which appears to
be required for a processive telomeric DNA synthesis
(Hammond et al., 1997). We have previously suggested a
model in which PS ODNs bind with high affinity to this
primer binding site, causing strong competitive inhibition
of primer binding to telomerase (Matthes and Lehmann,
1999). The efficiency of the PS ODNs in inhibiting telo-
merase activity of HL-60 cell lysates proved to be length
dependent rather than sequence dependent. Maximum in-
hibition was reached with a 20-mer PS ODN, which could
barely be increased by longer ODNs but could be de-
creased with decreasing length of the PS-ODN, resulting
in almost complete loss of inhibitory activity at the length
of a 6-mer PS ODN (Matthes and Lehmann, 1999).
Nonsequence-specific effects of PS ODNs frequently
are considered as a disadvantage for the application of PS
ODNs. However, the unique structure and function of
telomerase should allow the design of oligomers consist-
ing of PS ODNs extended at the 3-terminus by an
oligomer, hybridizing effectively to the neighboring tem-
plate region of RNA.
In this study, we have designed and studied chimeric
ODNs that combine protein-binding and RNA-binding
properties, thus retaining the high efficiency of PS ODNs
but providing the required specificity by an antisense part.
Furthermore, we present evidence that the polyanionic
character of PS ODNs and of heparin appears to be respon-
sible for inhibition of telomerase activity. We also describe
additive inhibitory effects when PS ODNs are given in
combination with antisense ODNs. The novel type of chi-
meric ODNs, which consist of 10–20-mer PS ODNs ex-
tended at the 3-end by unmodified or modified antisense
ODNs covering all 11 bases of the template site of telomer-
ase RNA, are powerful inhibitors of telomerase activity in
vitro and at the cellular level in U-87 glioblastoma cells.
Our strategy to target the primer binding site as well as
the RNA template of telomerase by chimeric ODNs was
followed by Tarkanyi et al. (2005). These authors used 4-
thiouridylate-oligomers instead of PS ODNs for binding
to the protein site of telomerase. In agreement with our
results, they demonstrate that in dependence on the
length of the 4-thiouridylate part, chimeric ODNs in-
crease the inhibitory activity of simple antisense ODNs
on telomerase activity.
MATERIALS AND METHODS
Cell incubations and cell extracts
Human glioblastoma cells U-87 were plated at 9  103
cells/well in 24-well plates in EMEM supplemented with
5% basal medium supplement, 2 mM GlutaMax (Life
Technologies, Gaithersburg, MD), 10% heat-inactivated
fetal bovine serum (FBS), 100 U/ml penicillin, and 100
g/ml streptomycin at 37°C in a 5% CO2 atmosphere.
Adherent cells were washed twice with phosphate-
buffered saline (PBS), trypsinized, counted, lysed with
CHAPS buffer (10 mM Tris-HCl, pH 7.5, 1 mM MgCl2,
1 mM EGTA, 0.1 mM benzamidine, 5 mM -mercap-
toethanol, 0.5% 3-[(3-cholamidopropyl)dimethyl-ammo-
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nio]-1-propane sulfonate, 10% glycerol [Intergen, Pur-
chase, NY]) (1  106/200 l), and centrifuged as de-
scribed (Matthes and Lehmann, 1999). The supernatants
used for the determination of telomerase activity were
aliquoted and stored at 80°C.
For transient transfection of ODNs, the adherent cells
were washed with EMEM and incubated for 4 hours with
lipofectin/ODN complex in 0.4 ml EMEM supplemented
by 3% FBS at 37°C and 5% CO2 in air. To prepare the
complex, each of the components—the ODN (up to 10
M) and the lipofectin (2.5/5 mg) (Life Technologies)—
was diluted in 50 l serum-free EMEM according to the
manufacturer’s instructions. Both solutions were mixed,
kept at ambient temperature for 15 minutes and overlaid
onto cells (covered with 0.3 ml EMEM/4% FBS). After
removal of the transfecting mixture, the cells were
washed (1  0.3 ml PBS, 3  0.25 ml serum containing
medium) and further incubated for 20 hours in 1 ml com-
plete EMEM. Cells were washed (2  0.25 ml PBS),
trypsinized, pelleted, washed again (2  0.25 ml PBS,
1  0.5 ml PBS), counted, lysed, and stored as described.
Oligomers
All HPLC-purified PS ODNs (for sequences, Scheme
1B; for structures, Scheme 2B) were provided by BioTez
(Berlin, Germany) and Eurogentec (Seraing, Belgium).
The PNA oligomer T9/U4/PNA (for sequence, Scheme
1A; for structure, Scheme 2F) was synthesized and puri-
fied by TIB MOLBIOL (Berlin, Germany), and its iden-
tity was confirmed by mass spectrometry (PerSeptive
Biosystems, Hamburg, Germany). The PS-linked abasic
oligomer consists of 19 abasic deoxyribosyl units
(dSpacer) and one deoxyguanosyl residue at the 3-end
(Scheme 1E and Scheme 2E). The latter was used for
synthesis because a corresponding dSpacer solid support
has not been available. The abasic oligomer was synthe-
sized and HPLC purified by Eurogentec. Heparin was
obtained from Sigma Chemical Co. (St. Louis, MO) or
from Fluka Chemie AG (Buchs, Switzerland).
Antisense ODNs, chimeric ODNs, and ODNs with
uniform backbones (Scheme 1, A, C, D; Scheme 2 A, B,
C, D) were synthesized in our laboratory on an Applied
Biosystems 391 DNA Synthesizer (PerSeptive Biosys-
tems, Framingham, MA) using 5-O-cyanoethyl phos-
phoroamidite chemistry.
The four 3-(trityl)amino-2, 3-dideoxynucleoside 5-
N, N-diisopropyl(2-cyanoethyl) phosphoramidites re-
quired for the synthesis of N3  P5 phosphoramidate-
modified ODNs were prepared as described (Nelson et
al., 1997). 3-O-(Dimethoxytrityl)-2-deoxynucleoside
5-N, N-diisopropyl-(2-cyanoethyl)phosphoramidites, 5-
O-(dimethoxytrityl)-2-O-methyl-ribonucleoside 3-N, N-
diisopropyl(2-cyanoethyl) phosphoramidites, solid sup-
ports, and reagents were purchased from Glen Research
(Sterling, VA). In the synthesis cycle, the N3  P5 phos-
phoramidate-modified oligomers were built in the 5–3-di-
rection. Coupling time was 20 minutes in the phosphor-
amidite amine exchange process (Gryaznov and Letzinger,
1999). The resulting internucleotide phosphoramidite was
then oxidized to the stable phosphoramidate. Unreacted 
3-amino groups were capped with isobutyric anhydride/
N-methylimidazole. PS linkages were generated by using
tetraethylthiuram disulfide as the sulfurization reagent (Vu
and Hirschbein, 1991).
All PAM-modified ODNs were isolated by ion ex-
change (IE) HPLC on a Shimadzu 10 VA series chro-
matograph. For analytic IE analysis, a Dionex PA-100
NucleoPac column (250  4 mm) was used, with a gra-
dient of 0–50% buffer B vs. buffer A over 45 minutes at
a flow rate of 1 ml/min. Buffer A was 0.01 M NaOH,
0.01 M NaCl, pH 12; buffer B was 0.01 M NaOH, 1.5 M
NaCl, pH 12. Preparative IEC of the oligomers was per-
formed on a Mono Q 10/10 column (Pharmacia, Uppsala,
Sweden) with a gradient as described.
The purity of the oligomers was proven by polyacry-
lamide gel electrophoresis (PAGE) analysis with a Bio-
metra P 25 electrophoresis apparatus. Gels were 20%
acrylamide-bis (ratio 20:1), 0.006% w/v ammonium per-
oxydisulfate, and 0.06% w/v N,N,N,N-tetramethyl eth-
ylenediamine in 7 M urea and 40 mM Tris-borate, pH 8.2.
The purified ODNs were analyzed by mass spectrometry
on a PE Biosystems Voyager System 4041 STR instru-
ment. As an example, for a PAM-modified ODN with the
sequence 5-AGTTAGGGTTAG-3, the
molecular weight found by MALDI TOF mass spectrome-
try was 3728 Da, which correlated well with the calculated
value of 3729 Da. In the case of the chimeric PS-phosphor-
amidate ODN 5-T*C*A*G*A*T*T*A*G*T*A*C*T*
C*G*T*C*A*G*A*TCAGATACAGA-3
the calculated value was 9838 Da, and the molecular
weight found by mass spectrometry was 9803 Da. Some
of the ODNs were analyzed by 31P-NMR. The spectrum
of the PS-phosphoramidate chimera with the sequence 5-
A*C*T*G*C*T*C*A*G*G*AGTTAGGGT-
TAG-3 with trimethyl phosphite as internal standard
showed the incorporation of 10 PS linkages ( 53.51–54.44
ppm) and 11 phosphoramidate linkages ( 5.63–5.91). The
molecular weight of this chimera found by MALDI TOF
mass spectrometry was 6975 Da; the calculated value was
6980 Da.
Telomerase assay
Determination of human telomerase activity was based
on the TRAP assay (Telomeric Repeat Amplification
Protocol; Kim et al., 1994) using a TRAPeze detection
kit (Intergen) following a slightly modified protocol. In-
stead of 50 l, we used a 25-l assay volume that con-
tained 20 mM Tris-HCl, pH 8.3, 1.5 mM MgCl2, 63 mM
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SCHEME 2. CHEMICAL STRUCTURES OF THE INVESTIGATED OLIGONUCLEOTIDE DERIVATIVES
(A) Phospodiester (PO); (B) Phosphorothioate (PS); (C) N3  P5 phosphoroamidate (PAM); (D) 2-O-methyl-
ribonucleoside (2-OMe; X is O or S); (E) abasic oligomer; (F) peptide nucleic acid (PNA). N, nucleobase.
KCl, 0.05% Tween-20, 1 mM EGTA, 50 M dNTP, 1 l
5-32P-phosphate-labeled TS primer (5-AATCCGTC-
GAGCAGAGTT-3; final concentration 200 nM), 0.5 l
primer mix, cell extract of U-87 cells (5000 cell equiva-
lent), and the ODN to be tested (Matthes and Lehmann,
1999). The tubes were incubated for 10 minutes at 30°C,
and the reaction products were amplified by PCR and
separated on 10% polyacrylamide gels, followed by
quantification with a phosphorimager. Telomerase activ-
ity and the percentage of its inhibition by oligomers were
calculated as the ratio of intensities of telomerase ladder
bands to the intensities of the 36-bp internal standard
(Matthes and Lehmann, 1999).
The PNA T9/U4/PNA (for sequence, Scheme 1A) was
stored in TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) at
20°C, thawed, and heated at 55°C for 5 minutes, then
kept at ambient temperature for 30 minutes. It was added
to the U-87 cell lysates alone or together with another
oligomer and preincubated for 30 minutes at 25°C and
kept on ice until the TRAP assay was completed. The
samples were incubated for 30 minutes at 25°C. The telo-
merase reaction was stopped by heating at 94°C for 5
minutes. PCR was performed at 94°C for 45 seconds,
50°C for 45 seconds, and 72°C for 45 seconds for 25–28
cycles. The samples were kept for additional 10 minutes
at 72°C, then cooled on ice and subjected to elec-
trophoresis as described.
RESULTS
Inhibition of telomerase by polyanions
We have shown that single-stranded and double-
stranded PS ODNs inhibit human telomerase in a largely
sequence-independent but length-dependent manner. In-
stead of hybridizing to the RNA template, these ODNs
seem to compete effectively with the TS primer for bind-
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ing to the primer binding site of the enzyme (Matthes and
Lehmann, 1999).
To demonstrate that the sugar PS backbone and not
base recognition is the causative structural element lead-
ing to the described effects, we examined an oligomer
consisting only of the deoxyribosyl-PS backbone and
lacking the nucleic acid bases, except for a single gua-
nine at the 3-end, which was required for solid-phase
synthesis (see Materials and Methods) (Scheme 1E and
Scheme 2E). This abasic oligomer with 19 PS linkages
(backbone oligomer; 20BO/PS) strongly inhibited telo-
merase activity, with an IC50 value of 2.3 nM in U-87 cell
lysates, which is similar to the value observed for a nor-
mal nucleobase-containing 20-mer PS ODN (IC50  3.3
nM; for sequence, Scheme 1B).
Then, we investigated the inhibitory activity of the
abasic oligomer 20BO/PS in the presence of increasing
concentrations of the normal phosphodiester-linked TS
primer as described previously (Matthes and Lehmann,
1999). 20BO/PS inhibited telomerase activity competi-
tively with respect to the TS primer, suggesting that both
the normal TS primer and the abasic 20BO/PS oligomer
are competing for the same binding site (Fig. 1). The
binding constant of the TS primer (Km) was determined
to be 8.60 nM, and the value for the inhibitory constant
(Ki) of the abasic oligomer (20BO/PS) was 1.49 nM. The
Km/Ki ratio indicates an about 3.4-fold higher affinity of
the 20BO/PS for the primer binding site than for the TS
primer. As the TS primer contains unmodified phospho-
diester linkages, the increased affinity of the abasic
oligomer may be ascribed to the PS backbone, which
affinity may result from the highly increased lipophilicity
of the PS linkage.
These results prompted us to investigate heparin as an-
other polyanionic compound having no nucleobases. This
sulfated polysaccharide is available only as a mixture of
polymers of different chain length, resulting in a broad
range of molecular weights. For the most active heparin
(Sigma) (MW about 4,000–30,000), the IC50 value was
0.06  0.01 g/ml. The lower-MW heparins (Fluka)
(MW 4,000–6,000; MW 3,000) were less inhibitory
(IC50  0.2–0.8 g/ml). The very strong effect of heparin
seems not to be caused by inhibition of the PCR, as am-
plification of the internal standard was not influenced up
to a concentration of 0.2 g/ml (data not shown).
Additive effects of oligomers binding to
telomerase-protein and telomerase-RNA,
respectively
It is conceivable that a combination of drugs targeting
two different binding sites on a heteromolecular target,
such as telomerase, might produce additive effects. In or-
der to test the hypothesis that PS ODNs and antisense
ODNs could target different sites of telomerase and cause
enhanced inhibition, we examined a combination of PS
ODNs and antisense ODNs in a TRAP assay with U-87
cell lysates for their efficacy against human telomerase
activity.
Figure 2A (left) demonstrates the inhibitory activity of
both oligomers alone: 1 nM of a 20-mer PS ODN
(20n/PS; for sequence, Scheme 1B) having no comple-
mentarity to the RNA template of telomerase and of dif-
ferent concentrations of an unmodified antisense ODN
covering 11 bases of the template region (T11) and two
adjacent downstream bases (D2) of RNA (termed
D2/T11/PO; for sequence, Scheme 1A). Because of the
results obtained with an abasic PS ODN analog, the non-
complementary PS ODN was expected to bind to the pro-
tein part, and the antisense PO ODN was expected to
bind in a sequence-dependent way to the RNA part of
telomerase. The IC50 value for D2/T11/PO antisense
ODN was 5.3 nM. When administered in combination,
their inhibitory activity increased nearly additively (Fig.
2A, right).
The same was true for the abasic oligomer (20BO/PS)
when combined with a PNA oligomer complementary to
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FIG. 1. Kinetics of inhibition of human telomerase by a PS-
linked abasic oligomer consisting of 19 abasic deoxyribosyl
sugar units and one deoxyguanosyl residue at the 3-end
(20BO/PS). A double reciprocal plot is shown of TS primer
concentration-dependent reaction velocities without inhibitor
(open circles) and in the presence of 1.0 nM 20BO/PS (closed
circles) and 2.5 nM 20BO/PS (closed squares), respectively.
The intensities of the individual lanes were measured as photo-
stimulated luminescence units (PSL) and quantitated as de-
scribed (Matthes and Lehmann, 1999).
nine bases of the RNA template and four adjacent up-
stream bases (T9/U4/PNA; for sequence, Scheme 1A).
As PNA has a neutral backbone, it was not expected to
show the nonsequence-dependent protein binding ob-
served for PS ODN and other polyanionic oligomers,
such as heparin. This PNA oligomer alone was described
previously as the most active inhibitor of human telomer-
ase, with an IC50 of 0.9 nM at 25°C (Norton et al., 1996).
In our hands, it proved to be less active (IC50  6.5 nM
for HL-60 cell lysates [Matthes and Lehmann, 1999] and
IC50  6.0 nM for U-87 cell lysates, both at 25°C). The
inhibitory activity of T9/U4/PNA was further increased
by the addition of 1 nM of the abasic 20BO/PS oligomer
(Fig. 2B), suggesting that the neutral PNA and the poly-
anionic abasic PS ODN do not compete for the same
binding site on telomerase.
Chimeric ODNs as inhibitors of telomerase
Based on these results, we designed and synthesized
chimeric oligomers in which the two active components
were linked together to yield a chimeric ODN: the PS-
modified ODN for targeting the protein’s polyanion
binding site and the antisense ODN for targeting the
RNA template of telomerase. The PS-modified part con-
sisted of sequences of different length (10-mer, 15-mer,
20-mer) that were unable to bind to the template region
of the RNA (10n/PS, 15n/PS, 20n/PS; Scheme 1B). The
3-parts of the chimeras were either 5-GTTAGGGT-
TAG-3, complementary to the 11 bases of the RNA tem-
plate (indicated by T11), or 5-TCAGATACAGA-3,
noncomplementary to the RNA template (indicated by
11n). The PS ODNs (Scheme 1B) and their extended chi-
meric counterparts (Scheme 1C.1, C.2) were examined as
inhibitors of telomerase activity in U-87 cell lysates. The
IC50 values are given in Table 1. In each case, the 3-
antisense part increased the efficiency of the pure PS
ODNs. The IC50 value of 10n/PS decreased from 22.0
nM to 2.3 nM for the chimeric ODN elongated by 11 
antisense bases with natural phosphodiester linkages
(10n/PS/T11/PO). Modifications of the antisense part of
the chimeric ODNs, aimed to increase the affinity to the
RNA (by 2-OMe/PO, by 2-OMe/PO/3PS, or by re-
placement of all PO-internucleotide linkages by PAM
[Scheme 1C.1]) did not change their inhibitory effects
substantially, despite the known increased binding affin-
ity of 2-OMe-modified or PAM-modified oligomers to
RNA.
Longer PS ODNs alone (15-mer, 20-mer) exhibited
better efficacy (IC50  6.5 nM and 3.3 nM) than the
shorter 10n/PS ODN. Nevertheless, their 3-antisense ex-
tensions further increased their inhibitory activity
3.5–8.6-fold (Table 1; IC50  0.6–1.0 nM). Again, the
type of modification did not significantly influence their
efficiency. Figure 3 shows an example of the concentra-
tion-dependent effects of 15n/PS/T11/PAM in compari-
son to 15n/PS on telomerase activity in the TRAP assay.
When the antisense sequence of the chimeric ODNs was
replaced by a noncomplementary sequence (Scheme
1C.2), the inhibitory effect caused by the antisense part
was abolished almost completely (Table 1, italics).
As additional controls to the chimeric ODNs ( 21-mer,
26-mer, and 31-mer), we examined oligomers of the
same length and sequence but with uniform backbones
(Scheme 1D). The IC50 values were 287 nM for a 21-mer
PAM-modified ODN (10n/PAM/T11/PAM), 21.4 nM
for an unmodified 26-mer ODN (15n/PO/T11/PO), and
34 nM for a 31-mer 2-OMe-modified ODN (20n/
2-OMe/PO/T11/2-OMe/PO). We further compared the
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FIG. 2. Effects of two oligomers addressing different targets
of telomerase. Inhibitory activity was given for single and com-
bined application: (A) 1 nM 20n/PS and different concentra-
tions of D2/T11/PO; (B) 1 nM 20BO/PS (an abasic sugar-PS
backbone oligomer; see Materials and Methods) and different
concentrations of T9/U4/PNA. Mean values of at least two dif-
ferent experiments are shown. For sequences, modifications,
and abbreviations of the oligomers, see Scheme 1.
chimeric ODNs with antisense ODNs covering either 11
bases of the RNA template alone (T11) or 2 additional
downstream bases (D2/T11) in an unmodified/modified
form that were considered the most effective ODNs (Pitts
and Corey, 1998; Herbert et al., 1999, 2002). Their IC50
values (Table 2) demonstrate that they were less efficient
than the comparable chimeric ODNs (Table 1). The only
exception is the unmodified antisense ODN D2/T11/PO
(IC50  5.3 nM), which was found to be equally active as
the chimeric ODN 10n/PS/T11/PAM (IC50  5.0 nM).
Inhibition by chimeric ODNs of telomerase
activity in U-87 cells
We examined at the cellular level if chimeric ODNs,
compared with PS ODNs and some antisense ODNs,
were capable of suppressing telomerase activity 20 hours
after transfection with ODN-lipofectin complexes. For
this, U-87 cells proved to be most appropriate, as shown
by the high uptake of a 5-FITC-labeled chimeric ODN
(20n/PS/T11/2-OMe/PO) into nuclei of U-87 cells 4
hours after transfection with lipofectin (data not shown).
The 10n/PS oligomer alone and its chimeric counter-
part extended by an 11-mer unmodified antisense part
were nearly inactive at the cellular level (ID50  2.25
M) (Table 3). The same was true for all T11 antisense
ODNs (Table 2) (T11/PO, T11/2-OMe/PO, and T11/
PAM; ID50  2.0 M) and D2/T11 antisense ODNs
(D2/T11/PO, ID50  2.0 M; D2/T11/2-OMe/PO,
ID50  1.2 M; D2/T11/PAM, ID50  2.0 M). In con-
trast, extensions of the 10n/PS ODN by modified anti-
sense oligomers increased strongly its intracellular in-
hibitory effect (ID50  0.49–0.70 M) (Table 3). The
same effects were found with antisense extensions of the
15n/PS and 20n/PS ODNs, which alone gave ID50 values
of 2.25 M and 0.40 M, respectively. The modified
antisense extensions (T11) of the 15n/PS ODNs showed
ID50 values between 0.35 and 0.60 M. For the 20n/PS,
extended by the modified antisense sequence, we found
ID50 values between 0.04 and 0.08 M.
The most effective chimeric ODNs were 20n/PS/T11/
PAM (ID50  0.04 M), containing the complete phos-
phoramidate substitution in the antisense part, and the
20n/PS/T11/2-OMe/3PS (ID50  0.06 M), which was
completely 2-O-methyl modified in the antisense part
and carried three PS linkages at the 3-end. Without lipo-
fectin, however, these ODNs were almost inactive
(ID50  2 M). Replacement of the antisense sequence
(T11) of the chimeric ODNs by a noncomplementary one
(11n) reduced the effects to nearly that observed for the
PS ODNs (Table 3, italics).
DISCUSSION
Besides their sequence-dependent antisense effects, PS
ODNs display additional effects that appear to be caused
mainly by sequence-independent interactions with pro-
teins. Such PS ODN-protein complexes can be formed
particularly with proteins binding negatively charged
glycosaminoglycans, such as heparin.
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TABLE 1. IC50VALUES (nM) FOR INHIBITION OF TELOMERASE ACTIVITY IN U-87 CELL LYSATESa
Abbreviations 
of ODNs PS-ODNs /PO /2-OMe/PO /2OMe/PO/3PS /PAM
10n/PS 22.0
10n/PS/T11 2.3 2.0 1.8 5.0
10n/PS/11n 24.3 16.9 15.2 26.0
15n/PS 6.5
15n/PS/T11 1.0 0.80 0.76 0.90
15n/PS/11n 3.9 5.3 4.6 7.4
20n/PS 3.3
20n/PS/T11 NDc 0.85 0.60 0.95
20n/PS/11n 2.4 2.8 3.0 3.4
aInhibition by mismatched PS ODNs of different length in comparison to such extended at the 3-end with unmod-
ified/modified antisense oligomers complementary to 11 bases of RNA template (T11) or noncomplementary to the
template region (11n). For sequences and modifications, see Scheme 1.
bIC50 values were mean values of three independent experiments.
cND, not detectable, interference with PCR.
IC50,nM b
Backbone structure of the 3-extensions of PS-ODNs
Examples of heparin-binding proteins and receptors
are basic fibroblast growth factor (bFGF), platelet-de-
rived growth factor (PGDF), vascular endothelial growth
factor (VEGF) and its receptor, and the epidermal growth
factor receptor (EGFR) (Stein, 1996; Stein, 1997). These
proteins are able to bind PS ODNs with high affinity,
which might influence their function (Rockwell et al.,
1997). Similarly, such enzymes as HIV-RT or its associ-
ated RNase H can be inhibited by PS ODNs in a widely
sequence-independent manner (Majumder et al., 1989;
Cheng et al., 1991). Human telomerase appears to be a
further example of a heparin-binding protein that is in-
hibited very strongly by PS ODNs in a largely sequence-
independent manner (Norton et al., 1996; Matthes and
Lehmann, 1999). We assume a competitive interaction of
PS ODNs with the primer at the primer binding site of
telomerase protein (Matthes and Lehmann, 1999).
Here, we report on further findings supporting the
model that polyanionic structures of PS ODNs alone are
sufficient for the described effects. Thus, an oligomer
consisting of 20 deoxyribosyl units linked via PS groups
but lacking nucleobases (except one at the 3-end) was
sufficient to give the full inhibitory activity (abasic
oligomer) (20BO/PS, IC50  2.3 nM) of a 20-mer PS
ODN in U-87 cell lysates (20n/PS-ODN, IC50  3.3
nM). We have demonstrated that the abasic oligomer
20BO/PS inhibited telomerase activity competitively
with respect to TS primer. This effect was comparable to
that described earlier for 20n/PS-ODN (Matthes and
Lehmann, 1999). The binding constant of the TS primer
(Km) was determined to be 8.60 nM, and the Ki value was
1.49 nM. Thus, the Km/Ki ratio indicates an approxi-
mately 3.4-fold higher affinity of the 20BO/PS for the
primer binding site than the TS primer. Furthermore, we
have shown that heparin (MW about 4,000–30,000) in-
hibited telomerase activity with similar efficiency to
HIV-RNase H (IC50  0.06 g/ml) (Moelling et al.,
1989). The specific binding site of heparin at the telomer-
ase remains to be elucidated, however.
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FIG. 3. Inhibitory effects of 15n/PS/T11/PAM in comparison
to 15n/PS on telomerase activity from U-87 cell lysates. (A)
TRAP gel showing telomerase products after addition of differ-
ent concentrations of 15n/PS/T11/PAM or 15n/PS. The loca-
tion of the internal standard (IS) is indicated. The Lysis buffer
lane represents a negative control containing no cell extract.
The control lanes represent the positive controls without ODNs
for 100% telomerase activity. (B) Concentration-dependent in-
hibition of telomerase activity by 15n/PS/T11/PAM calculated
from the phosphorimaged lanes in (A), as described (Matthes
and Lehmann, 1999).
TABLE 2. CONCENTRATIONS OF ANTISENSE ODNS
REQUIRED FOR 50% INHIBITION OF TELOMERASE
ACTIVITY IN LYSATES AND IN INTACT U-87 CELLSa
Abbreviations U-87 cell lysates U-87 cells
of ODNs IC50,nMb ID50,Mb
T11/PO 35.0 2.0
D2/T11/PO 5.3 2.0
T11/2-OMe/PO 43 2.0
D2/T11/2-OMe/PO 42 1.2
T11/PAM 472 2.0
D2/T11/PAM 167 2.0
aThe ODNs cover 11 bases of the template RNA (T11)
or additionally 2 adjacent downstream bases (D2/T11).
For sequences and modifications, see Scheme 1.
bIC50 and ID50 values were mean values of three inde-
pendent experiments.
A
B
The sequence-independent effects of PS ODNs on
some proteins are often considered as being disadvanta-
geous for the application of PS ODNs as antisense thera-
peutics. In the case of telomerase, however, the close
neighborhood of the RNA template and the PS ODN
binding site of the protein did allow the design of a new
type of chimeric ODN combining the high affinity to
both the protein site and the RNA template site of telo-
merase. Such chimeric ODNs appear to take advantage
of the very high, although mainly sequence-independent,
affinity of PS ODNs against telomerase protein, as selec-
tivity can be provided by an antisense extension at the 3-
end of these PS ODNs that is targeted to the RNA part of
telomerase.
Prior to the synthesis and investigation of such chime-
ric ODNs, we tested a combination of two individual
oligomers targeting both sites of telomerase. We could
demonstrate that such combinations showed increased
inhibitory activity compared with the single oligomers.
This was true for the 20-mer PS ODN (20n/PS) and the
20-mer sugar PS abasic oligomer (20BO/PS). Their in-
hibitory efficacy in U-87 cell lysates increased in a nearly
additive manner when combined with the antisense
oligomers D2/T11/PO and T9/U4/PNA, respectively.
These results prompted us to synthesize chimeric PS
oligomers of variable length (10-mer, 15-mer, 20-mer),
which were extended at the 3-end by antisense oli-
gomers with different modifications covering 11 bases of
the template. Our data demonstrate that the inhibitory ef-
fects of all the PS ODNs (10-mer, 15-mer, and 20-mer)
can be increased by the antisense ODN extensions. The
largest additional effect was found for the 10-mer PS
ODN (up to 12.2-fold) followed by the 15-mer PS ODN
(up to 8.6-fold), and was lowest for the 20-mer PS ODN
(up to 5.5-fold). The structural modifications of the anti-
sense part (2-OMe, PAM) of the chimeric ODNs had
virtually no influence on their efficacy during the 10 min-
utes of incubation of the U-87 cell lysates.
Although the contribution of the antisense part to the
inhibitory effect diminished with increasing length of the
PS ODNs in all cases, it was much higher than expected
by simple addition of the individual effects. Investigation
of a series of controls indicated that the antisense se-
quence as well as the PS part both contribute to the potent
inhibitory activity of the chimeric ODNs.
1. Changing the complementary sequence of the anti-
sense part to a noncomplementary one resulted in chi-
meric ODNs that showed inhibitory activity compara-
ble to pure PS ODNs (10-mer, 15-mer, 20-mer)
(Table 1, italics).
2. ODNs of the same length (21-mer, 26-mer, 31-mer) and
sequence as the chimeric ODNs but characterized by
uniform backbone structures in both parts of the ODNs
(e.g., 21-mer PAM, 26-mer PO, 31-mer 2-OMe/PO)
displayed much less inhibitory activity, demonstrating
that the length of the ODNs with uniformly unmodi-
fied/modified backbone structures is not responsible for
the described effects of the chimeric ODNs.
3. In comparison, nearly all simple antisense ODNs (un-
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TABLE 3. ID50 VALUES (M) FOR INHIBITION OF TELOMERASE ACTIVITY IN U-87 CELLS 20 HOURS
AFTER TRANSFECTION WITH ODN-LIPOFECTIN COMPLEXESa
ID50,M b
Abbreviations
Backbone structure of the 3-extensions of PS-ODNs
Of ODNs PS ODNs /PO /2-OMe/PO /2-OMe/PO/3PS /PAM
10n/PS 2.25c
10n/PS/T11 2.25 0.70 0.51 0.49
10n/PS/11n 2.25 1.25 1.25 2.25
15n/PS 2.25
15n/PS/T11 0.71 0.60 0.35 0.37
15n/PS/11n 1.25 1.25 1.25 1.25
20n/PS 0.40
20n/PS/T11 0.26 0.08 0.06 0.04
20n/PS/11n 0.61 0.30 0.45 0.97
aMismatched PS-ODNs of different lengths, were compared with such extended at the 3-end with unmodified/
modified antisense oligomers complementary to 11 bases of RNA template (T11) or noncomplementary to the template
region (11n). For sequences and modifications, see Scheme 1.
bID50 values were mean values of three independent experiments.
cmeans 21%-39% inhibition at given concentration.
modified/modified as the antisense part of the chime-
ric ones) targeting the 11 bases of RNA template of
telomerase (T11) and 2 additional downstream bases
(D2/T11), respectively, were less active than the chi-
meric ODNs.
The results with these control ODN variants suggest
that both the antisense sequence and the PS part are re-
quired for the described effects of chimeric ODNs. Fol-
lowing our strategy, Tarkanyi et al. (2005) found that chi-
meric ODNs in which 4-thiouridylate oligomers instead
of PS ODNs were used for binding to the protein site of
telomerase strengthen the inhibitory activity of simple
antisense ODNs in dependence on the length of the 4-
thiouridylate part.
Antisense ODNs with a PAM-modified backbone have
been described as excellent antisense oligomers with 
increased affinity and specificity for various RNA tar-
gets and a high nuclease stability (Gryaznov, 1999). Sur-
prisingly, PAM-modified antisense ODNs targeting the
RNA template of telomerase proved to be less active 
than all other antisense ODNs in our U-87 cell lysates
(e.g., T11/PAM, IC50  472 nM; and D2/T11/PAM,
IC50  167 nM) (Table 2). This finding is unexpected, 
as the previously described PAM-modified antisense
ODNs (corresponding to D2/T11 and T9/U4) showed
high binding affinity to complementary RNA in vitro
and potent antisense inhibition in intact cells, although
direct inhibitory effects on telomerase activity in vitro
have not been described (Herbert et al., 2002). In con-
trast, when PAM-modified ODNs were linked to the PS
ODNs (10-mer, 15-mer, 20-mer), the resulting chimeric
ODNs proved to be very powerful inhibitors of telomer-
ase activity in U-87 cell lysates (IC50  5.0 nM, 0.90 nM,
0.95 nM).
Although we cannot provide direct evidence for our
model, we hypothesize that binding of the PS part to the
primer binding site might increase the accessibility of the
RNA template to the antisense part of chimeric ODNs.
The most effective oligomers in this study were
20n/PS/T11/2-OMe/PO/3PS, 15n/PS/T11/2-OMe/PO/
3PS, and 15n/PS/T11/2-OMe/PO with IC50 values of
0.60–0.80 nM (Table 1). This ranking of telomerase inhi-
bition changed when chimeric ODNs were delivered in
U-87 cells by ODN-lipofectin complexes. This might be
caused by differences in cellular uptake, intracellular sta-
bility against nucleases, and length and target accessibil-
ity of the chimeric ODNs. Pure 10n/PS and 15n/PS
oligomers proved to be nearly inactive, whereas 20n/PS
gave an ID50 value of 0.40 M when exposed for 20
hours. The antisense extensions increased the efficiency
of the PS ODNs also in the cellular assay, here, however,
in dependence on the kind of modification.
Chimeric ODNs with an antisense sequence carrying
the 2-OMe modification and phosphodiester linkages at
the 3-end proved to be less potent at the cellular level
than those chimeras with three terminal PS or PAM-
modified antisense parts. The enhanced activity is likely
caused by the higher nuclease stability of the latter
(Gryaznov, 1999; Peymann and Uhlmann, 1996). The
20-mer PS ODN extended by nuclease-stable antisense
oligomers showed the most potent inhibition of telomer-
ase at the cellular level 20 hours after exposure (20n/
PS/T11/PAM, ID50  0.04 M; 20n/PS/T11/2OMe/PO/
3PS, ID50  0.06 M; 20n/PS/T11/2-OMe/PO, ID50 
0.08 M, against ID50  0.40 M for 20n/PS alone)
(Table 3). Changing the complementary sequence of the
antisense part to a noncomplementary part resulted in
chimeric ODNs that were active only in the range of pure
PS ODNs (10-mer, 15-mer, 20-mer) (Table 3, italics),
thus underlining the essential influence of the antisense
part on the activity of the chimeric ODNs at the cellular
level.
It is important to note that in contrast to the chimeric
ODNs, pure antisense ODNs, directed to telomerase
RNA (T11, D2/T11, unmodified or modified) (Table 2),
showed at the cellular level ID50 values as high as 1.2 up
to 2 M. In comparison, ID50 values of about 0.5–1
M for inhibition of telomerase activity in immortalized
human breast cells after 24 hours incubation with PAM-
modifed ODNs (corresponding to T11 and T9/U4, re-
spectively) were described recently (Herbert et al., 2002).
In conclusion, the superior activity of the novel chime-
ric ODNs targeting two different sites of telomerase com-
pared with simple antisense ODNs makes them attractive
candidates for more detailed studies of inhibiting tumor
growth.
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